The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Open accessAbstract
Background & aims Some patients with nonalcoholic fatty liver disease (NAFLD) develop liver-related complications and have higher mortality than other patients with NAFLD. We determined the accuracy of simple, noninvasive scoring systems in identification of patients at increased risk for liver-related complications or death.Methods We performed a retrospective, international, multicenter cohort study of 320 patients diagnosed with NAFLD, based on liver biopsy analysis through 2002 and followed through 2011. Patients were assigned to mild-, intermediate-, or high-risk groups based on cutoff values for 2 of the following: NAFLD fibrosis score, aspartate aminotransferase/platelet ratio index, FIB-4 score, and BARD score. Outcomes included liver-related complications and death or liver transplantation. We used multivariate Cox proportional hazard regression analysis to adjust for relevant variables and calculate adjusted hazard ratios (aHRs).Results During a median follow-up period of 104.8 months (range, 3-317 months), 14% of patients developed liver-related events and 13% died or underwent liver transplantation. The aHRs for liver-related events in the intermediate-risk and high-risk groups, compared with the low-risk group, were 7.7 (95% confidence interval [CI]: 1.4-42.7) and 34.2 (95% CI: 6.5-180.1), respectively, based on NAFLD fibrosis score; 8.8 (95% CI: 1.1-67.3) and 20.9 (95% CI: 2.6-165.3) based on the aspartate aminotransferase/platelet ratio index; and 6.2 (95% CI: 1.4-27.2) and 6.6 (95% CI: 1.4-31.1) based on the BARD score. The aHRs for death or liver transplantation in the intermediate-risk and high-risk groups compared with the low-risk group were 4.2 (95% CI: 1.3-13.8) and 9.8 (95% CI: 2.7-35.3), respectively, based on the NAFLD fibrosis scores. Based on aspartate aminotransferase/platelet ratio index and FIB-4 score, only the high-risk group had a greater risk of death or liver transplantation (aHR = 3.1; 95% CI: 1.1-8.4 and aHR = 6.6; 95% CI: 2.3-20.4, respectively).Conclusions Simple noninvasive scoring systems help identify patients with NAFLD who are at increased risk for liver-related complications or death. NAFLD fibrosis score appears to be the best indicator of patients at risk, based on HRs. The results of this study require external validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Six retrospective cohort studies on individuals with biopsy-proven MASLD showed that NFS and FIB-4 predict the occurrence of liver-related events (AUROCs from 0.72 to 0.86) and overall mortality (AUROCs from 0.67 to 0.82), 176,177 with a similar or lower accuracy compared to histology.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Obesity and Cardiovascular Disease
Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.068 · Cited by 2,326
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
de Franchis, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.004 · Cited by 2,291
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Research works printed but not linked: 1
- Gedaly, 2012, Rising incidence of nonalcoholic steatoheptitis among patients transplanted for hepatocellular carcinoma in the United States, Hepatology, 56, 40A
Cited by
Sorted by citations
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
McPherson, S., Hardy, T., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.034 · Cited by 1,059
Musso, G., Gambino, R., Tabibian, J. H., Ekstedt, M., Kechagias, S., Hamaguchi, M., Hultcrantz, R. W., Hagström, H., Yoon, S. K., Charatcharoenwitthaya, P., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001680 · Cited by 741
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
Wong, V. W., Adams, L. A., de Lédinghen, V., Wong, G. L., & Sookoian, S. C. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0014-9 · Cited by 617
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 641
Gómez, E. V., & Chalasani, N. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.013 · Cited by 608
Past, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Jarvis, H., Craig, D., Barker, R., Spiers, G., Stow, D., Anstee, Q. M., & Hanratty, B. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003100 · Cited by 434
Kwok, R., Tse, Y. ‐., Wong, G. L. ‐., Ha, Y., Lee, A. U., Ngu, M. C., Chan, H. L. ‐., & Wong, V. W. ‐. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12569 · Cited by 405
Boursier, J., Vergniol, J., Guillet, A., Hiriart, J.-B., Lannes, A., Le Bail, B., Michalak, S., Chermak, F., Bertrais, S., Foucher, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.023 · Cited by 400
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study
Loomba, R. S., Schork, N. J., Chen, C., Bettencourt, R., Bhatt, A., Ang, B., Nguyen, P., Hernandez, C., Richards, L., Salotti, J., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.011 · Cited by 388
Management of NAFLD: a stage-based approach
Rinella, M. E., & Sanyal, A. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.3 · Cited by 393
Lee, J., Vali, Y., Boursier, J., Spijker, R., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2020) · Liver International · doi:10.1111/liv.14669 · Cited by 400
Sanyal, A. J., Friedman, S. L., McCullough, A. J., & Dimick‐Santos, L. (2014) · Hepatology · doi:10.1002/hep.27678 · Cited by 360
Mantovani, A., Zaza, G., Byrne, C. D., Lonardo, A., Zoppini, G., Bonora, E., & Targher, G. (2017) · Metabolism · doi:10.1016/j.metabol.2017.11.003 · Cited by 348
Advances in non-invasive assessment of hepatic fibrosis
Loomba, R. S., & Adams, L. A. (2020) · Gut · doi:10.1136/gutjnl-2018-317593 · Cited by 351
Lee, Y., Jung, K. S., Kim, S. U., Yoon, H.-J., Yun, Y., Lee, B., Kang, E. S., Han, K., Lee, H. C., & Soo, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.051 · Cited by 340
Sberna, A.-L., Bouillet, B., Rouland, A., Brindisi, M., Nguyen, A., Mouillot, T., Duvillard, L., Denimal, D., Loffroy, R., Vergès, B. L., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13565 · Cited by 322
Kanwal, F., Kramer, J. R., Li, L., Dai, J., Natarajan, Y., Yu, X., Asch, S. M., & El‐Serag, H. B. (2020) · Hepatology · doi:10.1002/hep.31014 · Cited by 319
Spengler, E. K., & Loomba, R. S. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.013 · Cited by 294
Petroff, D., Blank, V., Newsome, P. N., Shalimar, Voican, C. S., Thiele, M., de Lédinghen, V., Baumeler, S., Chan, W. K., Perlemuter, G., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30357-5 · Cited by 268
Liver fibrosis scores predict liver disease mortality in the United States population
Ünalp–Arida, A., & Ruhl, C. E. (2017) · Hepatology · doi:10.1002/hep.29113 · Cited by 261
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Kabbany, M. N., Selvakumar, P. K. C., Watt, K. D. S., López, R., Akras, Z., Zein, N. N., Carey, W., & Alkhouri, N. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.5 · Cited by 247
Boursier, J., Hagström, H., Ekstedt, M., Moreau, C., Bonacci, M., Cure, S., Ampuero, J., Nasr, P., Tallab, L., Canivet, C. M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.031 · Cited by 206
Non-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 215
NAFLD and Chronic Kidney Disease
Marcuccilli, M. E., & Chonchol, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040562 · Cited by 201
Nonalcoholic fatty liver disease: Evolving paradigms
Lonardo, A., Nascimbeni, F., Maurantonio, M., Marrazzo, A., Rinaldi, L., & Adinolfi, L. E. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6571 · Cited by 204
Younes, R., Caviglia, G. P., Govaere, O., Rosso, C., Armandi, A., Sanavia, T., Pennisi, G., Liguori, A., Francione, P., Gallego-Durán, R., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.008 · Cited by 196
Hagström, H., Talbäck, M., Andreasson, A., Walldius, G., & Hammar, N. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.008 · Cited by 182
Simon, T. G., Henson, J., Osganian, S., Masia, R., Chan, A. T., Chung, R. T., & Corey, K. E. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.061 · Cited by 180
Yu, M., Lin, C., Liu, C., Yang, S.-H., Tseng, Y.-L., & Wu, C. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.001 · Cited by 176
Biomarkers in Nonalcoholic Fatty Liver Disease
Neuman, M. G., Cohen, L. B., & Nanau, R. M. (2014) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2014/757929 · Cited by 175
Serra‐Burriel, M., Juanola, A., Serra-Burriel, F., Thiele, M. S., Graupera, I., Pose, E., Pera, G., Grgurević, I., Caballería, L., Piano, S. S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01174-1 · Cited by 176
Karlas, T., Petroff, D., Garnov, N., Böhm, S. K., Tenckhoff, H., Wittekind, C., Wiese, M., Schiefke, I., Linder, N., Schaudinn, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091987 · Cited by 169
Chang, Y., Cho, Y. K., Kim, Y., Sung, E., Ahn, J., Jung, H., Yun, K. E., Shin, H. C., & Ryu, S. (2018) · Hepatology · doi:10.1002/hep.30170 · Cited by 162
Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.029 · Cited by 164
Stal, P. I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11077 · Cited by 162
Yang, B.-L., Wu, W.-C., Fang, K., Wang, Y., Huo, T., Huang, Y., Yang, H., Su, C., Lin, H.-C., Lee, F., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120443 · Cited by 158
Non-Alcoholic Fatty Liver Disease
Weiß, J., Rau, M., & Geier, A. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0447 · Cited by 166
Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
Kaswala, D. H., Lai, M., & Afdhal, N. H. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4079-4 · Cited by 161
Becker, P. P., Rau, M., Schmitt, J., Malsch, C., Hammer, C., Bantel, H., Müllhaupt, B., & Geier, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142661 · Cited by 154
Current and Future Burden of Chronic Nonmalignant Liver Disease
Udompap, P., Kim, D., & Kim, W. R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.015 · Cited by 153
Rasmussen, D. N., Thiele, M. S., Johansen, S., Kjærgaard, M., Lindvig, K. P., Israelsen, M. E., Antonsen, S., Detlefsen, S., Krag, A. A., Anastasiadou, E., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.037 · Cited by 150
Noninvasive assessment of liver fibrosis in NAFLD
Sanyal, A. J., Castera, L., & Wong, V. W.-S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.042 · Cited by 157
Nonalcoholic Fatty Liver Disease
Bril, F., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.005 · Cited by 158
Effects of resveratrol and other polyphenols in hepatic steatosis
Aguirre, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7366 · Cited by 143
Ekstedt, M., Nasr, P., & Kechagias, S. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0378-2 · Cited by 141
Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030
Alswat, K., Aljumah, A. A., Sanai, F. M., Abaalkhail, F. A., Alghamdi, M., Hamoudi, W. A., Khathlan, A. A., Quraishi, H. A., Rifai, A. A., Zaabi, M. A., et al. (2018) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_122_18 · Cited by 141
The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease
Iqbal, U., Perumpail, B. J., Akhtar, D. H., Kim, D., & Ahmed, A. (2019) · Medicines · doi:10.3390/medicines6010041 · Cited by 143
Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults
Marengo, A., Jouness, R. I. K., & Bugianesi, E. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.010 · Cited by 136
Golovaty, I., Tien, P. C., Price, J. C., Sheira, L. A., Seligman, H. K., & Weiser, S. D. (2019) · Journal of Nutrition · doi:10.1093/jn/nxz212 · Cited by 136
Dang, K., Hirode, G., Singal, A. K., Sundaram, V., & Wong, R. J. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000380 · Cited by 135
Trivedi, P. J., Bruns, T., Cheung, A., Li, K.-K., Kittler, C., Kumagi, T., Shah, H., Corbett, C., Al-Harthy, N., Acarsu, U., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.029 · Cited by 132
Hagström, H., Nasr, P., Ekstedt, M., Stål, P., Hultcrantz, R., & Kechagias, S. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.030 · Cited by 132
Athyros, V. G., Τζιόμαλος, Κ., Katsiki, N., Doumas, M. N., Karagiannis, A. I., & Mikhailidis, D. P. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.6820 · Cited by 132
Non-alcoholic fatty liver disease and the interface between primary and secondary care
Tsochatzis, E. A., & Newsome, P. N. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30077-3 · Cited by 130
Vodkin, I., Valasek, M. A., Bettencourt, R., Cachay, E. R., & Loomba, R. S. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13052 · Cited by 129
for the Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD), Ishiba, H., Sumida, Y., Tanaka, S., Yoneda, M., Hyogo, H., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1474-y · Cited by 130
Lessons from Epidemiology: The Burden of Liver Disease
Rowe, I. A. C. (2017) · Digestive Diseases · doi:10.1159/000456580 · Cited by 126
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
Bédossa, P., & Patel, K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.008 · Cited by 125
Bertot, L. C., Jeffrey, G. P., de Boer, B., MacQuillan, G. C., Garas, G., Chin, J., Huang, Y., & Adams, L. A. (2018) · Liver International · doi:10.1111/liv.13739 · Cited by 121
Shili‐Masmoudi, S., Wong, G. L., Hiriart, J., Liu, K., Chermak, F., Shu, S. S., Foucher, J., Tse, Y., Bernard, P., Yip, T. C., et al. (2019) · Liver International · doi:10.1111/liv.14301 · Cited by 117
Hafliðadóttir, S., Jonasson, J. G., Norland, H., Einarsdottir, S., Kleiner, D. E., Lund, S. H., & Bjornsson, E. S. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-166 · Cited by 116
Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?
Tomah, S., Alkhouri, N., & Hamdy, O. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-020-00097-1 · Cited by 122
Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327777 · Cited by 110
Aller, R., Fernández‐Rodríguez, C., Iacono, O. L., Bañares, R., Abad, J., Carrión, J. A., García‐Monzón, C., Caballería, J., Berenguer, M., Rodríguez‐Perálvarez, M., et al. (2018) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2017.12.003 · Cited by 120
Aspirin use is associated with lower indices of liver fibrosis among adults in the United States
Jiang, Z. G., Feldbrügge, L., Tapper, E. B., Popov, Y. V., Ghaziani, T., Afdhal, N. H., Robson, S. C., & Mukamal, K. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13515 · Cited by 106
Nonalcoholic fatty liver disease – current status and future directions
Demir, M., Lang, S., & Steffen, H. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12291 · Cited by 105
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Arrese, M. A., Arab, J. P., Francisco Barrera, M., Kaufmann, B. K., Valenti, L. V. C., & Feldstein, A. E. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730927 · Cited by 109
Barbosa, J. V., Milligan, S. C., Frick, A., Broestl, J., Younossi, Z. M., Afdhal, N. H., & Lai, M. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001606 · Cited by 101
Sebastiani, G., Alshaalan, R., Wong, P. Y. N., Rubino, M., Salman, A., Metrakos, P. P., Deschênes, M., & Ghali, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128774 · Cited by 99
Panahi, Y., Kianpour, P., Mohtashami, R., Atkin, S. L., Butler, A. E., Jafari, R., Badeli, R., & Sahebkar, A. (2018) · Phytotherapy Research · doi:10.1002/ptr.6073 · Cited by 95
Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD
Barbosa, J. V., Milligan, S. C., Frick, A., Broestl, J., Younossi, Z. M., Afdhal, N. H., & Lai, M. (2021) · Hepatology Communications · doi:10.1002/hep4.1841 · Cited by 94
QUAPAS: An Adaptation of the QUADAS-2 Tool to Assess Prognostic Accuracy Studies
Lee, J., Mulder, F. I., Leeflang, M., Wolff, R. F., Whiting, P. F., & Bossuyt, P. M. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0276 · Cited by 102
Lai, M., & Afdhal, N. H. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.02.002 · Cited by 92
From the origin of NASH to the future of metabolic fatty liver disease
Geier, A., Tiniakos, D., Denk, H., & Trauner, M. (2021) · Gut · doi:10.1136/gutjnl-2020-323202 · Cited by 80
Alkhouri, N., Mansoor, S., Giammaria, P., Liccardo, D., López, R., & Nobili, V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104558 · Cited by 89
Xu, X., Jiang, L., Wu, C., Pan, L., Lou, Z., Peng, C., Dong, Y., & Ruan, B. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.07.013 · Cited by 88
Crossan, C., Majumdar, A., Srivastava, A., Thorburn, D., Rosenberg, W. M., Pinzani, M., Longworth, L., & Tsochatzis, E. A. (2019) · Liver International · doi:10.1111/liv.14198 · Cited by 87
Irvine, K. M., Wockner, L. F., Shanker, M., Fagan, K. J., Horsfall, L. U., Fletcher, L. M., Ungerer, J. P. J., Pretorius, C. J., Miller, G. C., Clouston, A. D., et al. (2015) · Liver International · doi:10.1111/liv.12896 · Cited by 86
Weng, S. F., Kai, J., Guha, I. N., & Qureshi, N. (2015) · Open Heart · doi:10.1136/openhrt-2015-000272 · Cited by 84
Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis
Czaja, A. J. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12592 · Cited by 86
Castéra, L., Chan, H. L., Chan, Y., Arrese, M. A., & Han, K. (2015) · Cited by 83
Castéra, L. (2018) · Liver International · doi:10.1111/liv.13658 · Cited by 83
Kim, D., Kim, W. K., Adejumo, A., Cholankeril, G. T., Tighe, S. P., Wong, R. J., Gonzalez, S. A., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2019) · Hepatology International · doi:10.1007/s12072-018-09926-z · Cited by 81
Chen, Q., Li, Q., Li, D., Chen, X., Liu, Z., Hu, G., Wang, J., & Ling, W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.010 · Cited by 81
Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease
Papagianni, M. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i4.638 · Cited by 80
Bhat, M., Tazari, M., & Sebastiani, G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185192 · Cited by 80
Ewid, M., Sherif, H. M., Allihimy, A. S., Alharbi, S. A., Aldrewesh, D. A., Alkuraydis, S. A., & Abazid, R. M. (2020) · BMC Research Notes · doi:10.1186/s13104-020-05031-3 · Cited by 78
Kim, D., Vazquez‐Montesino, L. M., Escober, J. A., Fernandes, C. T., Cholankeril, G. T., Loomba, R. S., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000654 · Cited by 78
McPherson, S., Armstrong, M. J., Cobbold, J. F., Corless, L., Anstee, Q. M., Aspinall, R., Barclay, S. T., Brennan, P. N., Cacciottolo, T. M., Goldin, R. D., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00061-9 · Cited by 92
Önnerhag, K., Hartman, H., Nilsson, P. M., & Lindgren, S. C. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1583366 · Cited by 76
Metadata
- Authors
- Angulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J.
- Affiliations
- University of Kentucky HealthCare (US)
- University of Turin (IT)
- National University Hospital of Iceland (IS)
- Siriraj Hospital (TH)
- Gartnavel General Hospital (GB)
- Newcastle University (GB)
- The University of Sydney (AU)
- Corresponding author
- Angulo, Paul
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 145
- Issue
- 4
- Pages
- 782-789.e4
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC3931256
- OpenAlex
- W2129639561
- Cited by
- 502
- References
- 32
- Citations by year
- 2026: 7 · 2025: 29 · 2024: 31 · 2023: 32 · 2022: 46 · 2021: 60 · 2020: 49 · 2019: 40 · 2018: 39 · 2017: 35 · 2016: 36 · 2015: 49 · 2014: 45 · 2013: 4
- FWCI
- 32.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institutes of Health (R01 DK82426)
- Seventh Framework Programme (HEALTH-F2-2009-241762)
- National Health and Medical Research Council (1049857, 632630)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, NAFLD fibrosis score, FIB-4, BARD score, liver complications, mortality, liver transplantation, disease progression, prognosis, liver fibrosis, risk stratification, prognostic accuracy
- MeSH terms
- Adult, Fatty Liver, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Cohort Studies, Kaplan-Meier Estimate, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
